Clinical Research Directory
Browse clinical research sites, groups, and studies.
HS235 Study in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction
Sponsor: 35Pharma Inc
Summary
Study of HS235 in Overweight and Obese Participants with Combined Pre and Post-Capillary Pulmonary Hypertension due to Heart Failure with Preserved Ejection Fraction
Official title: Phase 1b/2, Multicenter, Double-Blind, Placebo-Controlled, Multiple Dose Study Assessing the Pharmacokinetics, Safety, Pharmacodynamics, and Efficacy of HS235 in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
126
Start Date
2026-09
Completion Date
2030-01
Last Updated
2026-09-29
Healthy Volunteers
No
Interventions
HS235
Subcutaneous Injection
Placebo
Subcutaneous Injection
Locations (2)
Investigational Site-105
Kansas City, Missouri, United States
Investigational Site-101
Greenville, South Carolina, United States